Barclays PLC Has $529,000 Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Barclays PLC lifted its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 279.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,580 shares of the biopharmaceutical company's stock after buying an additional 48,316 shares during the quarter. Barclays PLC owned about 0.13% of Theravance Biopharma worth $529,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Quantbot Technologies LP acquired a new stake in Theravance Biopharma in the 3rd quarter valued at approximately $60,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Theravance Biopharma by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 3,696 shares during the last quarter. Hsbc Holdings PLC bought a new position in Theravance Biopharma during the second quarter worth $108,000. Ballentine Partners LLC bought a new position in Theravance Biopharma during the third quarter worth $104,000. Finally, XTX Topco Ltd acquired a new position in Theravance Biopharma during the 2nd quarter valued at $129,000. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Stock Up 1.7 %

NASDAQ TBPH traded up $0.14 during midday trading on Friday, hitting $8.58. The company had a trading volume of 166,562 shares, compared to its average volume of 144,656. The firm has a fifty day simple moving average of $9.46 and a two-hundred day simple moving average of $8.89. Theravance Biopharma, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $10.44. The stock has a market cap of $421.88 million, a price-to-earnings ratio of -8.50 and a beta of 0.21.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.16). The firm had revenue of $16.87 million for the quarter, compared to analyst estimates of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same period last year, the business earned ($0.17) earnings per share. As a group, equities analysts predict that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 322,743 shares of the company's stock, valued at $2,904,687. The trade was a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.90% of the stock is currently owned by company insiders.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.